![]() This study is showing that in a specific subset of patients who received neoadjuvant chemotherapy overall survival can be further improved. The literature indicates that there is no difference in overall survival between either neoadjuvant chemotherapy or adjuvant chemotherapy. chemotherapy before definitive surgery or adjuvant chemotherapy i.e. Up till now breast cancer patients who have a high risk of recurrence are recommended to receive either neoadjuvant chemotherapy i.e. Summary: In this study, adjuvant capecitabine was shown to prolong disease-free survival and overall survival in HER2 negative patient who had residual disease following neoadjuvant therapy.Ĭonclusion: this is definitely a thought-provoking, and if confirmed by future trials it may lead to practice changing. The investigators recommend attention to the different pharmacokinetic profile of capecitabine between Asian and non-Asian patients and consideration of necessary dose modification when capecitabine used in Western patient population. The side effects noted and listed in the publication are the expected side effects of the capecitabine namely hand-foot syndrome and the usual hematologic toxicity, severe toxicity was noted rarely. hormone positive as well as hormone negative, for actual HR please refer to the study publication. The benefit of adding capecitabine in DFS and overall survival was seen in all subgroups i.e. At pre-specified interim analysis the primary endpoint of the study, disease-free survival (DFS), was met and the study was terminated. The basic results are summarized in the table above. The capecitabine dose was 1250/metered squared, twice a day, on days 1-14 q21 days, for six to eight cycles. Eligible patients were centrally randomized (1:1 between both arms) with balancing adjustment for tumor size at diagnosis, age, hormonal status(ER-positive vs ER-negative, neoadjuvant therapy type received, and also balanced with regard need or no need for endocrine therapy and or radiation therapy. the capecitabine arm and the control arm received standard therapy as indicated in the form of radiation therapy or endocrine therapy. Residual disease was defined as no complete response on pathological assessment or a complete response with positive lymph nodes. Received neoadjuvant chemotherapy with Anthracycline or taxane or both, followed by surgery.Stage I-IIIB before neoadjuvant therapy and surger.y.The study population were patients with the following eligibility criteria Study design: this was an open-label, multicenter study (in Japan and South Korea) randomized phase 3 trial. ![]() ![]() This is may be the first study to evaluate the benefit of further chemotherapy in such patients in improving disease-free survival and overall survival. CREAT-X, Capcetabine for Residual Cancer as Adjuvant Therapy trial is the first of it’s kind to look into further adjuvant chemotherapy in patients who received neoadjuvant chemotherapy.Ĭapecitabine adjuvant therapy is beneficial in Her2-negative Breast cancer with residual disease following Neoadjuvant therapy.īackground: I discussed neoadjuvant chemotherapy, at this moment the standard of care for patients who had residual disease following neoadjuvant chemotherapy does not include any further chemotherapy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |